Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Dopamine D2/3R availability after discontinuation of antipsychotic treatment: a [11C]raclopride PET study in remitted first-episode psychosis patients

Title: Dopamine D2/3R availability after discontinuation of antipsychotic treatment: a [11C]raclopride PET study in remitted first-episode psychosis patients
Authors: de Beer,Franciska; de Vries,Erik; Wijnen,Ben; Begemann, Marieke J H; van Beveren,Nico; Boonstra, Nynke; Gangadin,Shiral S; de Haan,Lieuwe; Hamers,Iris M H; Veling,Wim; Koops,Sanne; Sommer, Iris E C; Hersenen-Medisch 1
Publication Year: 2025
Subject Terms: Adult; Antipsychotic Agents/therapeutic use; Case-Control Studies; Corpus Striatum/metabolism; Dopamine D2 Receptor Antagonists; Female; Humans; Male; Positron-Emission Tomography; Psychotic Disorders/drug therapy; Raclopride; Receptors; Dopamine D2/metabolism; Dopamine D3/metabolism; Recurrence; Young Adult; Journal Article
Description: BACKGROUND: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D 2 receptor (D 2R) antagonist and partial agonist antipsychotics on striatal dopamine D 2/3R availability in FEP patients. METHODS: Remitted FEP patients underwent two [ 11C]raclopride PET scans to measure striatal D 2/3R availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users). Fifteen matched healthy controls were scanned once. Psychotic relapse was monitored up to 12 months after discontinuation. RESULTS: One week after discontinuation, D 2R antagonist discontinuers showed higher striatal binding potential (BP ND) than partial D 2R agonist discontinuers ( p < 0.001, CI=0.749 to 1.681) and controls ( p=0.045, CI=0.008 to 0.708), while partial agonist discontinuers had significantly lower BP ND than controls ( p=0.001, CI=-1.326 to -0.386). 6-8 weeks after discontinuation, former antagonist users showed similar BP ND to controls ( p > 0.25), whereas former partial agonist users had higher BP ND than controls ( p = 0.027, CI = 0.069 to 1.085). Participants who discontinued antagonists relapsed more often (81%) than those who discontinued partial agonists (17%)(χ 2 = 5.32, p = 0.021). CONCLUSIONS: Discontinuation of partial D 2R agonists may affect D 2/3R availability differently than discontinuation of antagonists, which might explain the greater relapse risk after tapering antagonists than partial agonist antipsychotics.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 0033-2917
Relation: https://dspace.library.uu.nl/handle/1874/467645
Availability: https://dspace.library.uu.nl/handle/1874/467645
Rights: info:eu-repo/semantics/OpenAccess
Accession Number: edsbas.3B55EC42
Database: BASE